Merus

Merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. Our most advanced development programs use the Biclonics® format. Biclonics® are capable of simultaneously attacking tumors in multiple ways. For example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways.

Company Growth (employees)

Type

Private

Utrecht, NL

Founded

2003

Size (employees)

63 (est)+4%

Website

merus.nl

Merus was founded in 2003 and is headquartered in Utrecht, NL

Merus Office Locations

Merus has an office in Utrecht

Utrecht, NL (HQ)

H.R. Kruytgebouw 8 Padualaan

Merus Data and Metrics

Summary Metrics

Founding Date	2003
Total Funding	$149.3 m
Latest funding size	$79.1 m
Time since last funding	about 2 years
Investors	Novartis Venture Fund, Life Sciences Partners, Johnson & Johnson Innovation, Aglaia Oncology Fund, Bay City Capital, Tekla Capital Management, RA Capital Healthcare, Novo A/S, Pfizer Venture Investments, Sofinnova Ventures, Rock Springs Capital, Pfizer